Search results
Results from the WOW.Com Content Network
Extended cycle use of COCPs may also be called menstrual suppression, [2] although other hormonal medications or medication delivery systems (hormonal intrauterine devices—IUDs) may also be used to suppress menses. Any brand of combined oral contraceptive pills can be used in an extended or continuous manner by simply discarding the placebo ...
This is a list of investigational obsessive–compulsive disorder drugs, or drugs that are currently under development for clinical use in the treatment of obsessive–compulsive disorder (OCD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
May also contain results of various clinical trials (studies) and/or explanations of the medication's effect on various populations (e.g. children, women, etc.). Indications and Usage - uses (indications) for which the drug has been FDA-approved (e.g. migraines, seizures, high blood pressure).
Lithium is approved by the FDA for the treatment of bipolar disorder and is widely prescribed off-label as a treatment for major depressive disorder, [12] often as an augmentation agent. Lithium is recommended for the treatment of schizophrenic disorders only after other antipsychotics have failed; it has limited effectiveness when used alone. [13]
Clomipramine, sold under the brand name Anafranil among others, is a tricyclic antidepressant (TCA). [7] It is used in the treatment of various conditions, most notably obsessive–compulsive disorder but also many other disorders, including hyperacusis, panic disorder, major depressive disorder, trichotillomania, [8] body dysmorphic disorder [9] [10] [11] and chronic pain. [7]
“Children will get into anything, and children will especially get into anything that tastes or looks like candy,” said Dr. Theresa Michele, who leads the FDA’s office of nonprescription drugs.
The one-time therapy, branded as Lenmeldy in the U.S., is approved for children in certain stages of disease progression, the Food and Drug Administration (FDA) said. US approves first gene ...
The gene therapy will compete with Australia-based CSL Behring’s Hemgenix, a similar treatment that won FDA approval for hemophilia B in 2022. That drug has a similar list price of $3.5 million ...